Literature DB >> 15205313

Adenovirus-mediated expression of antisense urokinase plasminogen activator receptor and antisense cathepsin B inhibits tumor growth, invasion, and angiogenesis in gliomas.

Christopher S Gondi1, Sajani S Lakka, Niranjan Yanamandra, William C Olivero, Dzung H Dinh, Meena Gujrati, C H Tung, Ralph Weissleder, Jasti S Rao.   

Abstract

We have shown previously that urokinase plasminogen activator receptor (uPAR) and cathepsin B are overexpressed during glioma progression, particularly at the leading edge of the tumor. In the present study, we simultaneously down-regulated uPAR and cathepsin B in SNB19 glioma cell monolayer or SNB19 spheroids using an adenoviral vector carrying antisense uPAR and antisense cathepsin B and a combination of these genes as determined by Western blot analysis. The Ad-uPAR-Cath B-infected cells revealed a marked reduction in tumor growth and invasiveness as compared with the parental and vector controls. In vitro and in vivo angiogenic assays demonstrated inhibition of capillary-like structure formation and microvessel formation after Ad-uPAR-Cath B infection of SNB19 cells when compared with Ad-cytomegalovirus (CMV)-infected or mock-infected controls. Furthermore, using a near infrared fluorescence probe, in vivo imaging for cathepsin B indicated low/undetectable levels of fluorescence after injection of the Ad-uPAR-Cath B construct into pre-established s.c. tumors as compared with Ad-CMV-treated and untreated tumors. The effect with bicistronic construct (Ad-uPAR-Cath B) was much higher than with single (Ad-uPAR/Ad-Cath B) constructs. These results indicate that the down-regulation of cathepsin B and uPAR plays a significant role in inhibiting tumor growth, invasion, and angiogenesis. Hence, the targeting of these two proteases may be a potential therapy for brain tumors and other cancers.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15205313     DOI: 10.1158/0008-5472.CAN-04-1243

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  31 in total

Review 1.  Specialized roles for cysteine cathepsins in health and disease.

Authors:  Jochen Reiser; Brian Adair; Thomas Reinheckel
Journal:  J Clin Invest       Date:  2010-10-01       Impact factor: 14.808

Review 2.  Engineered nanomaterial-induced lysosomal membrane permeabilization and anti-cathepsin agents.

Authors:  Melisa Bunderson-Schelvan; Andrij Holian; Raymond F Hamilton
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2017       Impact factor: 6.393

3.  Neuro-oncology in a nutshell.

Authors:  Joachim M Baehring
Journal:  J Neurooncol       Date:  2004-10       Impact factor: 4.130

Review 4.  Molecular optical imaging: applications leading to the development of present day therapeutics.

Authors:  Khalid Shah; Ralph Weissleder
Journal:  NeuroRx       Date:  2005-04

5.  Immunological thresholds in neurological gene therapy: highly efficient elimination of transduced cells might be related to the specific formation of immunological synapses between T cells and virus-infected brain cells.

Authors:  Carlos Barcia; Christian Gerdes; Wei-Dong Xiong; Clare E Thomas; Chunyan Liu; Kurt M Kroeger; Maria G Castro; Pedro R Lowenstein
Journal:  Neuron Glia Biol       Date:  2006-11

Review 6.  Cathepsin B as a cancer target.

Authors:  Christopher S Gondi; Jasti S Rao
Journal:  Expert Opin Ther Targets       Date:  2013-01-08       Impact factor: 6.902

7.  Downregulation of uPA, uPAR and MMP-9 using small, interfering, hairpin RNA (siRNA) inhibits glioma cell invasion, angiogenesis and tumor growth.

Authors:  Christopher S Gondi; Sajani S Lakka; Dzung H Dinh; William C Olivero; Meena Gujrati; Jasti S Rao
Journal:  Neuron Glia Biol       Date:  2004-05

8.  Sphingosine-1-phosphate regulates glioblastoma cell invasiveness through the urokinase plasminogen activator system and CCN1/Cyr61.

Authors:  Nicholas Young; Dennis K Pearl; James R Van Brocklyn
Journal:  Mol Cancer Res       Date:  2009-01       Impact factor: 5.852

9.  Latrunculin A and its C-17-O-carbamates inhibit prostate tumor cell invasion and HIF-1 activation in breast tumor cells.

Authors:  Khalid A El Sayed; Mohammad A Khanfar; Hassan M Shallal; A Muralidharan; Bhushan Awate; Diaa T A Youssef; Yang Liu; Yu-Dong Zhou; Dale G Nagle; Girish Shah
Journal:  J Nat Prod       Date:  2008-02-26       Impact factor: 4.050

10.  Cystatin E/M suppresses legumain activity and invasion of human melanoma.

Authors:  Jon J Briggs; Mads H Haugen; Harald T Johansen; Adam I Riker; Magnus Abrahamson; Øystein Fodstad; Gunhild M Maelandsmo; Rigmor Solberg
Journal:  BMC Cancer       Date:  2010-01-15       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.